Substance P and its inhibition in ocular inflammation

Fabio Bignami, Paolo Rama, Giulio Ferrari

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Neuropeptides, and specifically Substance P (SP), can crucially contribute to the ocular inflammatory response. SP is an undecapeptide that is secreted from sensory nerve endings and from various immune cells during inflammation. SP modulates ocular inflammation through its binding with the high-affinity neurokinin-1 receptor (NK-1R). This receptor is expressed on nerves, immune cells, and epithelial cells. SP is a key mediator of neurogenic inflammation as it induces increased microvascular permeability, vasodilatation, plasma extravasation, and subsequent tissue edema. In addition, macrophages can release inflammatory mediators such as interleukins, chemokines, and growth factors in response to SP stimulation. Inhibition of SP activity, either through blockade of the neuropeptide release or the use of SP receptor antagonists, ameliorates ocular inflammation, it restores immune privilege and improves a number of clinical endpoints associated with inflammation, such as corneal opacity, ocular perforation, and angiogenesis. This review of the literature will summarize the role of SP in the ocular inflammatory response (with an emphasis on the ocular surface). In addition, it will review the therapeutic effects of SP blockade to control ocular inflammation (i) in animal models and (ii) in highly prevalent human diseases.

Original languageEnglish
Pages (from-to)1265-1274
Number of pages10
JournalCurrent Drug Targets
Volume17
Issue number11
Publication statusPublished - Sep 1 2016

Fingerprint

Substance P
Inflammation
Neurokinin-1 Receptors
Neuropeptides
Neurokinin-1 Receptor Antagonists
Neurogenic Inflammation
Corneal Opacity
Inflammation Mediators
Macrophages
Interleukins
Opacity
Capillary Permeability
Therapeutic Uses
Sensory Receptor Cells
Chemokines
Vasodilation
Edema
Intercellular Signaling Peptides and Proteins
Animals
Animal Models

Keywords

  • Corneal neovascularization
  • Neurogenic inflammation
  • Neuropeptide
  • Ocular inflammation
  • Substance p
  • Tachykinins

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Substance P and its inhibition in ocular inflammation. / Bignami, Fabio; Rama, Paolo; Ferrari, Giulio.

In: Current Drug Targets, Vol. 17, No. 11, 01.09.2016, p. 1265-1274.

Research output: Contribution to journalArticle

@article{0931f0df6aca46068627196002caff44,
title = "Substance P and its inhibition in ocular inflammation",
abstract = "Neuropeptides, and specifically Substance P (SP), can crucially contribute to the ocular inflammatory response. SP is an undecapeptide that is secreted from sensory nerve endings and from various immune cells during inflammation. SP modulates ocular inflammation through its binding with the high-affinity neurokinin-1 receptor (NK-1R). This receptor is expressed on nerves, immune cells, and epithelial cells. SP is a key mediator of neurogenic inflammation as it induces increased microvascular permeability, vasodilatation, plasma extravasation, and subsequent tissue edema. In addition, macrophages can release inflammatory mediators such as interleukins, chemokines, and growth factors in response to SP stimulation. Inhibition of SP activity, either through blockade of the neuropeptide release or the use of SP receptor antagonists, ameliorates ocular inflammation, it restores immune privilege and improves a number of clinical endpoints associated with inflammation, such as corneal opacity, ocular perforation, and angiogenesis. This review of the literature will summarize the role of SP in the ocular inflammatory response (with an emphasis on the ocular surface). In addition, it will review the therapeutic effects of SP blockade to control ocular inflammation (i) in animal models and (ii) in highly prevalent human diseases.",
keywords = "Corneal neovascularization, Neurogenic inflammation, Neuropeptide, Ocular inflammation, Substance p, Tachykinins",
author = "Fabio Bignami and Paolo Rama and Giulio Ferrari",
year = "2016",
month = "9",
day = "1",
language = "English",
volume = "17",
pages = "1265--1274",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

TY - JOUR

T1 - Substance P and its inhibition in ocular inflammation

AU - Bignami, Fabio

AU - Rama, Paolo

AU - Ferrari, Giulio

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Neuropeptides, and specifically Substance P (SP), can crucially contribute to the ocular inflammatory response. SP is an undecapeptide that is secreted from sensory nerve endings and from various immune cells during inflammation. SP modulates ocular inflammation through its binding with the high-affinity neurokinin-1 receptor (NK-1R). This receptor is expressed on nerves, immune cells, and epithelial cells. SP is a key mediator of neurogenic inflammation as it induces increased microvascular permeability, vasodilatation, plasma extravasation, and subsequent tissue edema. In addition, macrophages can release inflammatory mediators such as interleukins, chemokines, and growth factors in response to SP stimulation. Inhibition of SP activity, either through blockade of the neuropeptide release or the use of SP receptor antagonists, ameliorates ocular inflammation, it restores immune privilege and improves a number of clinical endpoints associated with inflammation, such as corneal opacity, ocular perforation, and angiogenesis. This review of the literature will summarize the role of SP in the ocular inflammatory response (with an emphasis on the ocular surface). In addition, it will review the therapeutic effects of SP blockade to control ocular inflammation (i) in animal models and (ii) in highly prevalent human diseases.

AB - Neuropeptides, and specifically Substance P (SP), can crucially contribute to the ocular inflammatory response. SP is an undecapeptide that is secreted from sensory nerve endings and from various immune cells during inflammation. SP modulates ocular inflammation through its binding with the high-affinity neurokinin-1 receptor (NK-1R). This receptor is expressed on nerves, immune cells, and epithelial cells. SP is a key mediator of neurogenic inflammation as it induces increased microvascular permeability, vasodilatation, plasma extravasation, and subsequent tissue edema. In addition, macrophages can release inflammatory mediators such as interleukins, chemokines, and growth factors in response to SP stimulation. Inhibition of SP activity, either through blockade of the neuropeptide release or the use of SP receptor antagonists, ameliorates ocular inflammation, it restores immune privilege and improves a number of clinical endpoints associated with inflammation, such as corneal opacity, ocular perforation, and angiogenesis. This review of the literature will summarize the role of SP in the ocular inflammatory response (with an emphasis on the ocular surface). In addition, it will review the therapeutic effects of SP blockade to control ocular inflammation (i) in animal models and (ii) in highly prevalent human diseases.

KW - Corneal neovascularization

KW - Neurogenic inflammation

KW - Neuropeptide

KW - Ocular inflammation

KW - Substance p

KW - Tachykinins

UR - http://www.scopus.com/inward/record.url?scp=84983738203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983738203&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84983738203

VL - 17

SP - 1265

EP - 1274

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 11

ER -